Hyderabad-based pharma company has approached the Drug Controller General of India to seek Emergency Use Authorization for the investigational drug in India
Several research activities are being carried out to study Variants of Concern and assess their suitability for follow-up booster doses, the company said here on Tuesday.
The plea filed through advocate Prashant Bhushan sought direction to the government to make public the segregated data of the clinical trials for the vaccines.
The Nation's first indigenously developed DNA vaccine candidate against COVID-19, ZyCoV-D, by M/s Zydus Cadila has been approved by Drugs Controller General of India (DCGI), for the conduct of the Phase III clinical trials
Zydus Cadila has announced that the phase-I clinical trial of its vaccine candidate ZyCoV-D was over and it has commenced phase-II clinical trials from August.
According to the RDIF -- Russia's sovereign wealth fund, the vaccine's interim clinical trial results show 95 per cent efficacy on the 42nd day after the first dose.
Vaccine showed 90% efficacy in one dosing regimen when the vaccine was given as a half dose, followed by a full dose at least a month later, and another dosing regimen showed 62% efficacy when given as two full doses
The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3)